Nanobiotix, pioneer and leader in nanomedicine, has developed a revolutionary concept dedicated to the local treatment of cancer.

Nanobiotix is focused on the development of NanoXray, a pipeline of patented products, which are based on a physical mechanism of action: nanoparticles interact with X-rays and enhance the effect of radiotherapy within tumour cells.

Nanobiotix is listed on NYSE Euronext (NANO).